Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.61 |
| ▸ | DPP4 | P27487 | 4/20 | 0.60 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2961179 | 0.92 | HTR3A (0.53) | HTR3ADPP4SOS1PIM1KDM4E | |
| SCHEMBL27623275 | 0.85 | ALDH1A1 (0.47) | HTR3ADPP4KDM4ECYP1A2CYP2C9 | |
| SCHEMBL8352589 | 0.84 | HTR3A (0.61) | HTR3ADPP4SOS1PIM1 | |
| SCHEMBL13217380 | 0.83 | PIM1 (0.49) | HTR3ADPP4SOS1PIM1 | |
| SCHEMBL13200999 | 0.82 | HTR3A (0.62) | HTR3ADPP4SOS1PIM1 | |
| SCHEMBL13200858 | 0.81 | DPP4 (0.63) | HTR3ADPP4SOS1PIM1 | |
| SCHEMBL2962148 | 0.79 | ACHE (0.46) | KDM4ECYP1A2CYP2C9CYP2C19HSD17B10 | |
| SCHEMBL13200266 | 0.78 | DPP4 (0.55) | DPP4 | |
| SCHEMBL13200864 | 0.78 | HTR3A (0.58) | HTR3ADPP4SOS1PIM1CYP1A2 | |
| SCHEMBL4068476 | 0.78 | HTR3A (0.62) | HTR3ADPP4SOS1PIM1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | HTR3A 1879/4885DPP4 1/4885SOS1 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.